Exisulind

Generic Name: Exisulind

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₇FO_₄S

CAS Number: 59973-80-7

Unique Ingredient Identifier: K619IIG2R9

Indication: Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Exisulind
Drug: luteinizing hormone-releasing hormone (LHRH) agonist
Drug: Antiandrogen

First Posted Date: 2006-01-30

Last Posted Date: 2018-08-07

Lead Sponsor: University of Washington

Target Recruit Count: 32

Registration Number: NCT00283803

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Exisulind Versus Placebo After Surgical Removal of the Prostate

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 240

Registration Number: NCT00166426

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2004-06-17

Last Posted Date: 2011-10-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 600

Registration Number: NCT00085826

Locations: 🇺🇸
Oncology-Hematology Associates, Pittsburgh, Pennsylvania, United States
🇺🇸
Temple Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
The Texas Cancer Center - Dallas Southwest, Dallas, Texas, United States

and more 93 locations

Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-03-09

Last Posted Date: 2013-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00078910

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 1

Completed

Conditions: NSCLC

First Posted Date: 2003-11-07

Last Posted Date: 2011-10-20

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 52

Registration Number: NCT00072618

Locations: 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis

Phase 2

Withdrawn

Conditions: Colorectal Cancer
Small Intestine Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-24

Lead Sponsor: University of Utah

Registration Number: NCT00026468

Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: docetaxel
Drug: estramustine phosphate sodium
Drug: exisulind

First Posted Date: 2003-01-27

Last Posted Date: 2016-07-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 80

Registration Number: NCT00052845

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇨🇦
McGill University, Montreal, Quebec, Canada
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 77 locations

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: etoposide
Drug: exisulind

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 41

Registration Number: NCT00041054

Locations: 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 80 locations

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00041314

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

and more 76 locations

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Neoplasms
Metastases, Neoplasm

Interventions: Drug: Capecitabine
Drug: Exisulind

First Posted Date: 2002-05-20

Last Posted Date: 2012-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00037609

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy